期刊文献+

2型糖尿病患者非酒精性脂肪肝与微血管病变关系的研究 被引量:8

Non-alcoholic fatty liver disease is associated with chronic kidney disease and diabetic retinopathy in type 2 diabetic patients
暂未订购
导出
摘要 目的探讨2型糖尿病(T2DM)患者中非酒精性脂肪肝(NAFLD)与慢性肾脏疾病(CKD)及糖尿病视网膜病变(DR)的关系。方法收集2008年5月至2009年7月上海交通大学附属第一人民医院内分泌代谢科448例T2DM患者的临床资料,按是否合并NAFLD分组,比较两组间CKD和DR的发生率及其与NAFLD的联系。结果(1)448例T2DM患者中NAFLD合并率为59.4%。(2)与无NAFLD组相比,NAFLD组尿白蛋白/肌酐比值(UACR)及CKD和DR的发病率明显升高(P<0.01)。(3)Logistic回归分析显示,NAFLD是T2DM患者发生CKD和DR的独立危险因素(OR=1.9,P<0.05;OR=2.8,P<0.01)。结论T2DM患者中NAFLD与CKD和DR密切相关,提示通过早期诊断和干预NAFLD可预防微血管并发症。 Objective To investigate the relationship of non-alcoholic fatty liver disease (NAFLD) with chronic kidney disease(CKD) and diabetic retinopathy (DR) in type 2 diabetic patients. Methods Prevalenees of CKD and DR were assessed in 448 type 2 diabetic patients ,who were divided into two groups by the presence of NAFLD. Results ( 1 ) The prevalence of NAFLD was 59.4% in type 2 diabetic patients. (2) NAFLD patients had remarkably( P 〈 0. 01 ) higher urinary albumin/creatinine ratio ( UACR ) and prevalences of CKD ( 30. 8 vs 18. 1% ) and DR(35.7 vs 21.4% ) than their counterparts without NAFLD. (3)Logistic regression analysis showed that NAFLD was associated with increased incidences of CKD( OR = 1.9 ,P 〈0. 05) and DR( OR = 2. 8, P 〈 0. 01 ) independent of age, sex, diabetes duration, BMI, hypertension, smoking, HbA1 c and serum lipids. Conclusion NAFLD is associated with increased prevalences of CKD and DR in type 2 diabetic patients. Early i- dentification and intervention of NAFLD can help to prevent diabetic microvascular complications.
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2010年第1期41-43,共3页 Chinese Journal of Practical Internal Medicine
基金 国家自然科学基金(30700381) 上海市科委引领计划项目(74119638)
关键词 2型糖尿病 非酒精性脂肪肝病 慢性肾脏疾病 糖尿病视网膜病变 type 2 diabetes non-alcoholic fatty liver disease chronic kidney disease diabetic retinopathy
  • 相关文献

参考文献10

  • 1Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients [ J ]. Diabetes Care, 2007,30 (5) :1212 -1218.
  • 2Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association..非酒精性脂肪性肝病诊疗指南[J].中华肝脏病杂志,2006,14(3):161-163. 被引量:1518
  • 3Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease : evaluation, classification, and stratification [ J ]. Ann Intern Med, 2003, 139 ( 2 ) : 137 - 147.
  • 4赵琳,Dina Shrestha,张霞,王颖,孙崴,张萍,苏本利.2型糖尿病患者非酒精性脂肪肝患病率的回顾性分析[J].中国糖尿病杂志,2008,16(9):535-535. 被引量:36
  • 5Targher G, Bertolini L, Rodella S, et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients[ J]. Diabetologia,2008,51 (3) :444 - 450.
  • 6Leite NC,Salles GF, Araujo AL, et al. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus[ J]. Liver Int,2009,29( 1 ) :113 - 119.
  • 7Zou AP, Li N, Cowley AW Jr. Production and actions of superoxide in the renal medulla[ J ]. Hypertension,2001,37 (2) :547 - 553.
  • 8Ryu S, Chang Y, Kim DI, et al. gamma-Glutamyltransferase as a predictor of chronic kidney disease in nonhypertensive and nondiabetie Korean men[ J]. Clin Chem,2007,53( 1 ) :71 -77.
  • 9Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease [ J ]. Atherosclerosis, 2007, 191 (2) :235 -240.
  • 10Cheng AY, Kong AP, Wong VW, et al. Chronic hepatitis B viral infection independently predicts renal outcome in type 2 diabetic patients[ J ]. Diabetologia,2006,49 ( 8 ) : 1777 - 1784.

二级参考文献22

  • 1胡国平,刘凯,赵连三.多烯磷脂酰胆碱(易善复)治疗酒精性肝病和脂肪肝的系统评价[J].肝脏,2005,10(1):5-7. 被引量:108
  • 2Schwimmer JB,Behling C,Newbury R,et al.Histopathology of pediatric nonalcoholic fatty liver disease.Hepatology,2005,42:641-649.
  • 3Neuschwander Tetri BA,Caldwell SH.Nonalcoholic steatohepatitis:summary of an AASLD Single Topic Conference.Hepatology,2003,37:1202-1219.
  • 4Angulo P.Nonalcoholic fatty liver disease.N Engl J Med,2002,346:1221-1231.
  • 5Ghali P,Lindor KD.Hepatotoxicity of drugs used for treatment of obesity and its comorbidities.Semin Liver Dis,2004,24:389-397.
  • 6Harrison SA,Torgerson S,Hayashi P,et al.Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis.Am J Gastroenterol,2003,98:2485-2490.
  • 7Angulo P.Use of ursodeoxycholic acid in patients with liver disease.Curr Gastroenterol Rep,2002,4:37-44.
  • 8Agrawal S,Bonkovsky HL.Management of nonalcoholic steatohepatitis:an analytic review.J Clin Gastroenterol,2002,35:253-261.
  • 9Comar KM,Sterling RK.Drug therapy for non-alcoholic fatty liver disease.Aliment Pharmacal Ther,2006,23:207-215.
  • 10Lok AS,McMahon B J; Practice Guidelines Committee,American Association for the Study of Liver Diseases (AASLD).Chronic hepatitis B:update of recommendations.Hepatology,2004,39:857-861.

共引文献1546

同被引文献60

引证文献8

二级引证文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部